Biogen reports mixed results in mid‑stage trial of tau‑targeting Alzheimer’s therapy

Biogen disclosed data from a Phase 2 study of its experimental Alzheimer’s drug that targets the tau protein. The trial showed a combination of positive and negative signals, with some measures indicating potential benefit while others fell short of expectations.

The mixed outcome reflects the ongoing challenge of developing disease‑modifying therapies for Alzheimer’s, where both amyloid and tau pathways have proven difficult to translate into clear clinical success.

While the results are not a clear win, they provide valuable information for Biogen as it decides on next steps for the program, including possible trial redesign or additional studies.